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BACKGROUND. This study was conducted to determine whether the paranasal
extension of a primary non-Hodgkin’s lymphoma (NHL) of the nasal cavity has any
deleterious effect on patient outcome.
METHODS. One hundred and seventy-five patients with previously untreated
nasal NHL were reviewed. There were 2 with low grade, 107 with intermediate
grade, 17 with high grade, and 49 with unclassifiable lymphomas. In 48
cases the immunophenotype was available and 46 were T-cell lymphoma.
According to the Ann Arbor system, there were 133 patients with Stage IE, 28
with Stage IIE, 4 with Stage IIIE, and 10 with Stage IVE lymphomas. Stage IE
was subdivided into limited Stage IE (i.e., confined to the nasal cavity [67
patients]) or extensive Stage IE (i.e., presenting with extension beyond the nasal
cavity [66 patients]). For patients with limited Stage IE disease the treatment of
choice was radiotherapy with or without chemotherapy. In patients with ex-
tensive Stage IE disease, treatment was comprised of a combination of chemo-
therapy and radiotherapy or radiotherapy alone. For patients with a more
advanced stage of disease (IIE–IVE), chemotherapy was an integral part of the
treatment and was completed by irradiation, especially for patients with Stage
IIE disease.
RESULTS. The actuarial overall survival (OS) and disease free survival (DFS) rates
at 5 years for the whole group were 65% and 57%, respectively. The 5-year OS
and DFS rates were influenced by stage, with a gradual decrease from 75% and
68% for Stage IE disease to 35% and 28% for Stage IIE disease, and 31% and 19%
for Stage IIIE/IVE disease. Patients with limited Stage IE disease survived
significantly longer (90% 5-year OS) compared with those with extensive Stage
IE disease (57% 5-year OS; P , 0.001). For 67 patients with limited Stage IE
disease, the 5-year OS was 89% with radiotherapy alone and 92% with radio-
therapy and chemotherapy, whereas for 66 patients with extensive Stage IE
disease, the 5-year OS was 54% with radiotherapy and 58% with combined
modality therapy or chemotherapy (P . 0.05).
CONCLUSIONS. The prognosis of patients with primary NHL of the nasal cavity is
stage dependent. In this large cohort of Stage IE patients, it was demonstrated that
the paranasal local extension was a significant prognostic factor associated with
poorer treatment outcome. The authors believe that Ann Arbor Stage IE should be
subclassified further into limited and extensive Stage IE. The addition of chemo-
therapy did not appear to modify significantly the survival of patients with either
limited or extensive Stage IE disease. The extranodal progression observed in
patients with extensive Stage IE and Stage IIE-IVE disease clearly illustrates the
need for improvement of systemic treatment. Cancer 1998;83:449 –56.
© 1998 American Cancer Society.
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Primary non-Hodgkin’s lymphoma (NHL) of the na-sal cavity is a distinct clinicopathologic entity. As
an extranodal form of NHL, this disease is character-
ized by a predominance of T-cell phenotype, a fre-
quent association with Epstein-Barr virus (EBV) infec-
tion, and a poor prognosis.1–12 This particular form of
extranodal NHL appears to be relatively more resistant
to chemotherapy compared with other forms of
NHL.1,13 In contrast to lymph node NHL, no guide-
lines for treatment are established for NHL of the
nasal cavity.2,5,14 –16 The majority of published series
regarding the prognostic factors of NHL of the nasal
cavity do not address the effect of paranasal extension,
and there was little information regarding the corre-
lation between paranasal extension and progno-
sis.1,4,5,8,14,15 The purpose of this investigation was to
examine the significance of paranasal extension as a
prognostic factor. Therefore, we reviewed what is, to
our knowledge, one of the largest series in the world
literature of patients treated at the Cancer Hospital of
the Chinese Academy of Medical Sciences (CAMS) and
Peking Union Medical College (PUMC).
PATIENTS AND METHODS
From January 1983 to December 1995, 195 patients
with primary NHL of the nasal cavity were referred to
the Cancer Hospital of the CAMS and PUMC in Bei-
jing, China. These patients represent 10% of all pa-
tients with NHL at our institution. Patients were
deemed eligible provided they were not treated previ-
ously elsewhere. After review of pathologic slides, 175
previously untreated patients were considered for the
current analysis.
Stage
The patients were staged according to the Ann Arbor
system.17 To assess the prognostic value of paranasal
extension, we subclassified Ann Arbor Stage IE into
limited and extensive Stage IE. Limited Stage IE tu-
mors were confined to the nasal cavity, whereas ex-
tensive Stage IE tumors extended beyond the nasal
cavity and into the neighboring structures without any
sign of dissemination. For an adequate evaluation the
patients underwent a medical history, physical exam-
ination, blood chemistry, chest radiograph, and bone
marrow aspiration. Computed tomography (CT)
and/or ultrasound of the abdomen were performed
routinely. In addition, standard radiographs of the
bone skull and sinus tomograms as well as CT scans of
the head and neck were used systematically to assess
the paranasal extension. Chest CT was not routine, but
it was performed in 42 patients.
Management
Treatment options were dependent on the stage (Ta-
ble 1). Limited Stage IE disease primarily was treated
by external irradiation with or without consolidation
chemotherapy. For extensive Stage IE disease, com-
bined treatment including chemotherapy and radio-
therapy was preferred although some of these patients
were submitted to radiotherapy alone or chemother-
apy alone. In more advanced stage disease a combi-
nation of chemotherapy and radiotherapy (Stage IIE)
or first-line chemotherapy with adjuvant radiotherapy
(Stage IIIE and IVE) generally was used.
Radiotherapy initially was given with an 8-mega-
volt linear accelerator. The majority of the patients
received a dose of 50 –55 gray (Gy) with a range of
40 –70 Gy. In case of Stage IE disease limited to the
nasal cavity, a single anterior port including the nasal
cavity and the ipsilateral maxillary/ethmoid sinuses
was used in 37 patients. For the remaining 30 patients
with limited Stage IE disease, 2 lateral opposing fields
and an anteroposterior port were used. The latter
technique also was applied to the patients with exten-
sive Stage IE disease. For these particular patients as
well as for those with Stage IIE disease, the fields were
extended to encompass involved paranasal tissues or
cervical lymph nodes. Moreover, 27 of 133 Stage IE
patients received prophylactic cervical lymph node
irradiation.
Of 175 patients, 103 received chemotherapy in
combination with radiotherapy and 7 patients re-
ceived chemotherapy alone. Fifty-six patients were
TABLE 1
Treatment Options According to Stage
Stage
TotalLimited IE Extensive IE IIE IIIE/IVE
RT 39 19 5 2 65
RT 1 Chemo 28 45 22 8 103
Chemo 0 2 1 4 7
RT: radiotherapy; Chemo: chemotherapy.
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treated with a combination of bleomycin, 5 mg/m2
intravenously (i.v.), on Days 15 and 21; doxorubicin,
25 mg/m2 i.v., on Days 1 and 8; cyclophosphamide,
650 mg/m2 i.v., on Days 1 and 8; vincristine, 1.4
mg/m2 i.v., on Days 1 and 8; and prednisone, 60
mg/m2 orally on Days 15–28 (BACOP). Twenty-eight
patients received bleomycin, 5 mg/m2 i.v., on Days 15
and 21; etoposide, 60 mg/m2 i.v., on Days 1–5; cyclo-
phosphamide, 650 mg/m2 i.v., on Days 1 and 8; vin-
cristine, 1.4 mg/m2 i.v., on Days 1 and 8; and pred-
nisone, 60 mg/m2 orally on Days 15–28 (BECOP).
Sixteen patients received cyclophosphamide, 750
mg/m2 i.v., on Day 1; doxorubicin, 50 mg/m2 i.v., on
Day 1; vincristine, 1.4 mg/m2 i.v., on Day 1; and pred-
nisone, 100 mg orally on Days 1–5 (CHOP). Ten pa-
tients received less intensive regimens because of
poor performance status, advanced age, or compro-
mised cardiopulmonary function: cyclophosphamide,
750 mg/m2 i.v., on Days 1 and 8; vincristine, 1.4
mg/m2 i.v., on Days 1 and 8; bleomycin, 5 mg/m2 i.v.,
on Days 1 and 8; and prednisone, 40 mg/m2 orally on
Days 1–10 (COBP) in 2 patients and cyclophospha-
mide, 650 mg/m2 i.v., on Days 1 and 8; vincristine, 1.4
mg/m2 i.v., on Days 1 and 8; procarbazine, 100 mg/m2
orally on Days 1–14; and prednisone, 40 mg/m2 orally
on Days 1–14 (COPP) in 8 patients. Usually six cycles
of combination chemotherapy were administered in
cases of advanced stage disease. In contrast, patients
with limited Stage IE disease received two to four
cycles of consolidation chemotherapy after radiother-
apy.
Statistics
The median follow-up time was 70 months. Overall
survival (OS) and disease free survival (DFS) were es-
timated by the product-limit Kaplan-Meier method.18
Time was measured from the start of initial treatment
until the time of first local or distant failure or recur-
rence, last follow-up, or death. The significance of
differences between survival curves was calculated by
the log rank test.19 Multivariate analysis was per-
formed using the Cox model. Comparison of the qual-
itative data was performed by chi-square analysis.
RESULTS
Patient Characteristics
There were 115 males and 60 females, with a male-to-
female ratio of 2:1. The median age was 44 years
(range, 11–79 years). The right nasal cavity was in-
volved in 46 patients, the left in 70 patients, and both
in 59 patients (Table 2). The most frequent presenting
symptom was nasal obstruction. Locally advanced
NHL was more likely to be associated with aggressive
signs and symptoms including facial swelling, epi-
staxis, proptosis, hard palate perforation, B symptoms,
and cranial nerve palsy.
Paranasal extension was present in 105 patients
(60%). Of these, 66 patients (38%) had paranasal ex-
tension only, without any sign of lymph node or dis-
tant dissemination, and 39 patients (22%) had involve-
ment of lymph nodes or distant extranodal sites as
well. The large majority (39 of 42; 93%) of patients with
Stage IIE, IIIE, and IVE disease had paranasal exten-
sion, and only 3 patients (3 of 42; 7%) had their pri-
mary tumor limited to the nasal cavity. The organs or
TABLE 2






























Histologic subtypes according to Working Formulation
Small lymphocytic 2
Diffuse small cleaved cell 18
Diffuse mixed cell 60
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tissues most frequently involved by the primary tumor
were the maxillary sinus (70%), the ethmoid sinus
(60%), and the nasopharynx (41%). Approximately
42% of patients (73 of 175) had involvement of multi-
ple neighboring organs or tissues within the vicinity of
the primary tumor.
Overall, 21% of the patients (36 of 175) initially
presented with lymph node involvement, and 4 of
these patients had distant extranodal spread as well.
In 20 of these patients the submandibular lymph node
was involved, whereas 17 patients presented with pos-
itive cervical lymph nodes. Lymph nodes located in
the buccal area and in the parotid region were in-
volved less frequently, in three and one patients, re-
spectively. The distant extranodal sites of involvement
were observed in the skin, lung, liver, bone marrow,
and testis.
Survival
The 5-year OS and DFS were 65% and 57%, respec-
tively. According to the Ann Arbor classification,
5-year OS and DFS were 75% and 68%, respectively,
for Stage IE disease, 35% and 28%, respectively, for
Stage IIE disease, and 31% and 19%, respectively, for
Stage IIIE/IVE disease (Fig. 1). The difference in OS
and DFS between Stage IE and IIE disease was statis-
tically significant (P , 0.001). However, there was no
significant difference in OS and DFS between Stage IIE
and Stage IIIE/IVE disease (P 5 0.08). This partly is
due to the small numbers of patients in these sub-
groups.
The paranasal extension was a significant prog-
nostic factor in Stage IE patients. The 5-year OS and
DFS were 90% and 89%, respectively, for limited Stage
IE disease, and 57% and 45%, respectively, for exten-
sive Stage IE disease (P , 0.001) (Fig. 2). There also
was a significant difference in survival between exten-
sive Stage IE and Stage IIE disease (P , 0.05).
Chemotherapy, whether combined with radio-
therapy or alone, resulted in a 5-year OS of 59%. In
contrast, patients treated with radiotherapy alone
had a survival probability of 74%, but this merely
illustrates a difference in treatment prescription ac-
cording to stage. Considering 133 Stage IE patients
only, the 5-year OS difference was smaller between
treatment modalities, with an OS of 79% for radio-
therapy alone and 75% for the combined modality
therapy or chemotherapy alone. The breakdown in
Stage IE patients according to tumor extension and
treatment modality shows that for 67 patients with
limited Stage IE disease the 5-year OS with radio-
therapy alone was 89% compared with 92% for ra-
diotherapy and chemotherapy (Fig. 3). The corre-
sponding survival for 66 patients with extensive
Stage IE disease was 54% for radiotherapy alone
compared with 58% for chemotherapy or in combi-
nation with radiotherapy (Fig. 4). None of these
differences were statistically significant. However, it
might be worthwhile to note that there was a trend
toward better 5-year survival in the group of pa-
tients treated with chemotherapy, suggesting that
combined modality should be favored in patients
FIGURE 1. Overall survival according to Ann Arbor stage in patients with
non-Hodgkin’s lymphoma of the nasal cavity for Stage IE (n 5 133), Stage IIE
(n 5 28), and Stage IIIE/IVE (n 5 14) patients.
FIGURE 2. Overall survival in patients with limited Stage IE (n 5 67) and
extensive stage IE (n 5 66) disease.
FIGURE 3. Overall survival by treatment in patients with limited Stage IE
disease. RT: radiotherapy; CT: chemotherapy.
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with extensive Stage IE disease. A comparable anal-
ysis could not be performed for higher stage disease.
To assess the influence of prognostic factors on
OS and DFS, the following parameters were included
in the Cox regression analysis: age, gender, localiza-
tion, B symptoms, paranasal extension, Ann Arbor
stage, pathology, and chemotherapy. Only stage and
paranasal extension were significant prognostic fac-
tors for OS and DFS.
Patterns of Failure
Forty patients progressed during the initial therapy,
and 31 recurred between 2 and 78 months after treat-
ment. The majority of patients (22 of 31; 71%) recurred
within 2 years, and 3 recurred at . 5 years. Figure 5
shows the patterns of progression and recurrence in
63 available patients.
For the 15 patients with local progression or re-
currence, failure was located in the irradiated field in
11 whereas in 4 patients it was a marginal failure. Only
2 of 67 patients (3%) with limited Stage IE disease
developed local recurrence, whereas 9 patients with
extensive Stage IE disease local progression or recur-
rence.
Regional or distant lymph node failure was ob-
served in 17 patients; in 4 of these patients these
failures were located in the head and neck region.
Prophylactic neck irradiation (PNI) was not used in
106 of 133 Stage IE patients, 2 of whom developed
progression in the cervical lymph nodes, whereas
none of the remaining 27 Stage IE patients treated
with PNI developed cervical progression or recur-
rence. Systemic lymph node invasion was observed in
the axillary, inguinal, abdominal, pelvic, and su-
pratrochlear areas.
Distant extranodal dissemination was the primary
patterns of failure. Forty-nine patients (49 of 63; 78%)
developed a progression or recurrence in the extran-
odal sites including the skin, lung, liver, larynx, bone
marrow, brain, bone, and testis. Extranodal failure was
observed mainly in the skin (24 of 49 patients; 49%),
lung (8 patients), and liver (6 patients).
Fifty-six patients died of lymphoma. The origin of
death was progression in 35 patients and recurrence
in 21 patients. Seven patients died of other causes:
cerebral hemorrhage, cerebral thrombosis, myocar-
dial infarction, malignant reticulocytosis, hepatitis, ce-
rebral meningitis, and unknown cause.
DISCUSSION
Primary NHL of the nasal cavity is common in China,1
accounting for 10% of all NHL in the current study. In
contrast, it is rare in the U. S.5,20 As is the case with
nasopharyngeal carcinoma or lymphoma, the higher
incidence of nasal NHL in Asian individuals, might be
due to the high prevalence of EBV infec-
tion.4,7,10,12,21–24 As observed by other researchers, the
most common types are diffuse mixed and large cell
lymphomas.1,5,10 In contrast to primary lymphoma of
Waldeyer’s ring, which predominantly is of B-cell
type,25 NHL of the nasal cavity mainly is a T-cell lym-
phoma.8,9,14,26 With regard to pathology, nasal NHL is
characterized by angioinvasion and necrosis. The ex-
tensive necrosis, polymorphic cellular infiltration, and
small sizes of the biopsy samples usually make sub-
typing according to the Working Formulation quite
difficult.
Pathways of Tumor Spread
Patients with NHL of the nasal cavity usually present
at an early stage. However, these early stage tumors
often are a bulky primary tumor, and directly extend
into the neighboring organs and tissues. The involve-
ment of the maxillary and ethmoid sinuses is the most
FIGURE 4. Overall survival by treatment in patients with extensive Stage IE
disease. RT: radiotherapy; CT: chemotherapy.
FIGURE 5. Patterns of failure (progression and recurrence) in patients with
non-Hodgkin’s lymphoma of the nasal cavity.
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common mode of local extension. Conversely, the
probability of lymph node and distant extranodal
spread increases with extension of the primary tumors
outside the nasal cavity.
The major pathway of lymph node spread for NHL
of the nasal cavity is to the submandibular and cervi-
cal lymph nodes. This submandibular involvement
clearly is in contrast to Waldeyer’s ring lymphoma in
which the cervical lymph nodes are more often in-
volved.25,27 Moreover, we observed buccal and parotid
lymph node spread, which is an uncommon pathway
of involvement in other lymphoma. However, the re-
gional lymph node spread of primary NHL of the nasal
cavity appears to be consistent with the primary
drainage of the nasal cavity and adjacent structures
such as the maxillary and ethmoid sinuses.28
The propensity of nasal NHL spread to the skin
observed at presentation or during progression and
recurrence can be explained by the homing capacity
of T-lymphocytes that also explain the pattern of
spread of other extranodal lymphoma: Waldeyer’s ring
lymphomas spread to the gut, whereas lung lym-
phoma spreads to the gut and salivary gland.29,30
Management and Prognosis
The prognosis of nasal NHL has been reported to be
poor and in general patients with NHL of the nasal
cavity are reported to carry an aggressive lympho-
ma.1,8,14,16 This study of 175 patients with NHL of the
nasal cavity, which to our knowledge is the largest
series in the world literature, shows that the prognosis
is not uniformly poor and particularly that a subset of
patients with Stage IE disease confined to the nasal
cavity survives for long periods. Five-year OS and DFS
of 90% and 89%, respectively, were obtained when
these patients were treated with radiotherapy alone or
radiotherapy followed by 2– 4 cycles of consolidation
chemotherapy. Progression or recurrence rates were
low. Thus patients with nasal NHL with limited Stage
IE disease should be considered for treatment with
radiotherapy with curative intent. Radiotherapy alone
or combined with chemotherapy had a similar impact
on OS and DFS.
In comparison with patients with limited Stage IE
disease, patients with extensive Stage IE disease have
a relatively poor prognosis. Nevertheless, the survival
for patients with extensive Stage IE disease was signif-
icantly better than that for Stage IIE patients. In this
series, 67 of 94 patients with extensive Stage IE and
Stage IIE disease were treated with combined modal-
ity therapy, whereas 24 received radiotherapy alone
and 3 received chemotherapy alone. Furthermore, at
least 6 cycles of chemotherapy followed by radiother-
apy were given to 25 patients with extensive Stage IE
disease and 13 patients with Stage IIE disease. Al-
though no significant difference in survival was ob-
served between radiotherapy and combined modality
therapy, there is a suggestion that the latter improves
the treatment outcome for patients with extensive
Stage IE disease. Therefore it is our current policy to
combine both treatment modalities for these patients.
It is worthwhile to note that in Western countries,
chemotherapy followed by involved field radiotherapy
is administered to patients with locally advanced lym-
phoma.31,32 Recently, several studies have shown that
combined modality therapy is better than chemother-
apy alone for early stage intermediate and high grade
NHL.31–33
For patients with limited Stage IE disease who
primarily are treated with radiotherapy, we recom-
mend that the treatment volume include the whole
nasal cavity and the ipsilateral maxillary and ethmoid
sinuses. When the primary tumors are close to the
choanae, the nasopharynx is included. For patients
with primary tumor extending beyond the nasal cav-
ity, the treatment field is enlarged to encompass the
neighboring structures involved by the tumor. We do
not recommend prophylactic neck irradiation for
Stage IE patients because of the apparent low risk of
progression or relapse in the cervical lymph nodes in
our experience.
As observed by others,1,5 patients with Stage IIE
and IIIE/IVE disease have an extremely poor prog-
nosis. We recommend chemotherapy as primary
treatment with adjuvant irradiation to the primary
tumor for these patients. However, survival after 5
years is a rare event, and the use of chemotherapy
does not appear to change the uniformly fatal out-
come in Stage IIIE and IVE disease. Therefore, given
the fact that these patients in the current series were
treated with combination chemotherapy (i.e., doxo-
rubicin or etoposide-based regimens), one might
consider resistance to conventional chemotherapy
to produce any durable long term remissions in
these particular patients. It has been reported that
resistance to conventional chemotherapy in NHL of
the nasal cavity may be associated with frequent
expression of p-glycoprotein.13 Furthermore, loss of
p53 function also has been shown to be related to
drug resistance in NHL.34 Therefore, patients with
Stage IIIE and IVE NHL of the nasal cavity are can-
didates for novel treatment strategies or new agents
on a clinical trial. In view of the molecular biologic
mechanisms, one might consider the use of chemo-
therapeutic drugs independent of the multidrug re-
sistance gene-related efflux pump or strategies di-
rected toward p53 alteration.
Primary NHL of the nasal cavity is a distinct clin-
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ical entity, characterized by a predominance of male
and T-cell phenotype, frequent involvement of the
paranasal structures, and a high incidence of extran-
odal progression and recurrence. The prognosis is de-
pendent on the stage and paranasal extension. Pa-
tients with Stage IE disease confined to the nasal
cavity have a better survival compared with those with
Stage IE disease extending beyond the nasal cavity.
Patients with Stage IIE, IIIE, and IVE have a poor
prognosis that is not significantly influenced by the
use of conventional chemotherapy. To our knowledge,
this study demonstrates for the first time that progno-
sis in patients with Ann Arbor Stage IE disease de-
pends on the presence of paranasal extension. Con-
fined or superficial lesions, as is the case in other
extranodal sites such as NHL of the stomach, intes-
tine, and Waldeyer’s ring,15,35–38 are cured readily, but
spread beyond the boundaries of the primary organ,
often resulting in progressive lymphoma. Therefore,
Ann Arbor Stage IE NHL of the nasal cavity is subdi-
vided into limited and extensive Stage IE disease. Ex-
tensive paranasal extension can be considered to be
an independent prognostic factor in subsequent stud-
ies and most likely may be used for stratification of
patients.
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